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I L-I receptor heterogeneity in murine lymphocytes was investigated by cross-linking to [~25I]IL-1~ and competition with IL-1 receptor antagonist, 
and the molecular identity of the IL-1 receptors was identified with PCR using primers pecific for type I and type II IL-I receptors. The thymoma 
cell line EI4 6.1 exhibits exclusively the 80 kDa receptors which proved to be the type I receptor according to PCR analysis. In the pre-B cell line 
70Z/3, predominantly a 60 kDa type II receptor but also a trace of type I receptor can be identified by PCR. The Th2 cell line D10N expresses 
both types of IL-1 receptors in equivalent amounts according to cross-linking experiments and PCR. The proliferative response of D 10N cells to 
IL-1 is inhibited by IL-1 ra which according to cross-linking affects the binding to the type I receptor only. It is concluded that coexpression of 
both types of IL-1 receptors might be a characteristic of murine Th2 cells and that their growth-dependence on IL-I is mediated by the type I 
receptor. 
Interleukin-1 receptor; Interleukin-1; Interleukin-1 receptor antagonist; Mouse T helper cell 
1. INTRODUCTION 
IL-1 exerts its biological effects by means of at least 
two different receptors (for review see [1]). Two IL-1 
receptors from human and murine cell lines have been 
cloned and sequenced, an 80 kDa protein with an intra- 
cellular domain of 217 amino acid residues [2], the type 
I IL-1 receptor, and a second one of a 60 kDa protein 
with an extraordinarily short intracellular domain of 29 
amino acid residues, the type II IL-1 receptor [3]. For 
both types of receptors the mode of signaling remains 
to be established. 
Characteristically, the IL-1 receptors are distributed 
in a tissue-specific, often mutually exclusive manner 
[4,5]. In a murine T helper 2 (Th2) cell line D10A, a 
subline of D10.G4.1, however, IL-1 was shown to acti- 
vate separate signal transduction pathways [6]. Corre- 
spondingly the coexistence of 2 different IL-1 receptors 
on such cells has been implicated [6] and corroborated 
by differential blockade of IL-1 responses by M15, a 
monoclonal antibody directed against he 80 kDa type 
I IL-1 receptor [7]. In fact, an IL-1 receptor with a lower 
molecular weight apart from the 80 kDa IL-1 receptor 
has been detected in D10S cells [8] and D10.G4.1 cells 
[9] and according to peptide mapping analysis it was 
suggested to be a related, probably processed form of 
Correspondence address." R. Brigelius-Floh6, Medizinische Hoch- 
schule Hannover, Institut ffir Molekularpharmakologie, Konstanty- 
Gutschow-Str. 8, 30623 Hannover, Germany. Fax: (49)(511)532 794. 
the type I IL-1 receptor [10]. The identity of this second 
receptor in T helper cells thus appears not yet unequiv- 
ocally established. Also the possible coexistence of dif- 
ferent IL-1 receptors in T cells merits consideration 
since more recently the dogma that the type I receptor 
characterizes T cells, whereas the type II receptor is only 
found in B cells, has been challenged [11]. 
Here we have analyzed the IL-1 receptor heterogene- 
ity of D10N cells, another subline of D10.G4.1 [12] by 
cross-linking experiments, complemented with inhibi- 
tion studies using the IL-1 receptor antagonist (IL-lra). 
Further, we provide proof of identity of two IL-1 recep- 
tors in D10N cells by PCR technique. 
2. MATERIALS AND METHODS 
2.1. Reagents 
The murine T-helper (Th2) DION line is a subline of the D10.G4.1 
and was obtained from S.J. Hopkins, University of Manchester Rheu- 
matic Disease Center, Salford, UK.
Human recombinant IL-I~, IL-lfl and IL-lra were kind gifts from 
Dr. W.-D. Schleuning, Schering AG, Berlin, Dr. S. Gillis, Immunex, 
Seattle and Dr. D. Boraschi, Sclavo, Siena. 
2.2. Cell cultures 
The murine D10N cell line was cultured in RPM1, containing 10% 
(v/v) fetal calf serum (FCS), 50/IM fl-mercaptoethanol, 100 U/ml 
penicillin, 10ktg streptomycin/ml, 2 mM glutamine, 1ng IL-lfl/ml, 10 
U IL-2/ml and, if indicated, 3 ,ug ConA/ml at 37°C in a humidified 
95% air, 5% CO2 atmosphere. Before all experiments the DION cells 
were 'starved' for 24 h, i.e. incubated as above but without IL-I. 
EI 4 6.1 and 70Zl3 cell lines were cultured in RPMI, containing 5% 
FCS, and/J-mercaptoethanol, penicillin, streptomycin and glutamine 
as described above. 
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1 2 3 4 2.3. Covalent cross-l&king of [~25I]IL-lot to cells and gel electrophore- 
sis 
RhIL-I~ was labelled by the chloramine T method as described 
earlier [13]. Cells (2 5 x 107) were incubated for 4 h at 4°C with 20 ng 
[~25I]IL-lc~ in0.2-0.5 ml serum-free medium alone or in combination 
with unlabeled IL-lfl or IL-lra as indicated in the figures. They were 
then washed twice with ice-cold PBS. Dithiobis-succinimidyl suberate 
(DSS) in DMSO (prepared just prior to use) was added at a final 
concentration f 5 mM, and incubated for 1 further hour at 4°C. The 
cells were washed twice with ice-cold PBS and then lysed in PBS 
containing 1% Triton and 2 mM phenylmethyl-sulfonylfluoride 
(PMSF) for 15 rain. After centrifugation (800 x g, 15 rain) the super- 
natent was diluted with an equal volume SDS sample buffer, heated 
3 min, and run on a 8% SDS polyacrylamide g l (Laemmli). Gels were 
dried and autoradiographed. 
2.4. Proliferation assay 
Cells (2 2.5 x 104) 24 h starved for IL-1 (see above) were incubated 
in culture medium in a final volume of 200 pl containing the various 
concentrations of IL-I~ and IL-lra indicated in Fig. 4. After 72 h the 
cell proliferation was measured using the MTT procedure [14]. 
2.5. PCR 
Total RNA was isolated and cDNA from 1 ,ug RNA was prepared 
by reverse transcriptase and amplified using the PCR Gene Amp RNA 
PCR kit from Perkin-Elmer. 
Primers were obtained by the solid-phase oligonucleotide synthesis 
method of Adams et al. [15] using an Applied Biosystems 380B synthe- 
sizer. The location of the primers within the receptor is shown in Fig. 
3a. The DNA sequence of the type I receptor was taken from [2], for 
the type II receptor from the EMBL data base, accession umber 
X59769 [3]. 
Primers type I: 5'-CTGGAGATTGACGTATGTACAGAATA- 
TCCAAAT-3" 
and 
5'-ATCCCCGGCAATGTGGAGCCGCTGT- 
GGGAAGGTGGCCTGTGT3' 
type II: 5'-TTCACCACTCCAACAGTGGTGCACA- 
CAGGA-3' 
and 
5'-GTTCATCCTCTGTACTCCGTCTCTAC- 
GAAGTCA-Y 
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Fig. 1. Left part: Cross-linking of [125I]IL-lc~ to D10N cells. Lane 1, 
cells were cultured in the presence of ConA; lane 2, cells were cultured 
without ConA; lane 3, 3H-labelled protein standards of known molec- 
ular weight; lane 4, [~25I]IL-l~ alone. Right part: Cross-linking of 
[~25I]IL-cc to EI4 6.1 cells. Lane 1, standards; lane 2, E1 4 cells. 
3.2. IL-1 ra inhibits cross-linking o f  lL-lo~ on DION cells" 
to the type I IL-1 receptor only 
Since it was shown that the I L - l ra  has a greater affin- 
ity to the type I IL-1 receptor [16], we per formed cross- 
l ink ing inh ib i t ion  studies in the presence of  I L - l ra  to 
further character ize the nature  of  the two IL-1 receptors 
on D10N cells. For  this purpose the receptor  antagon is t  
was added to the b ind ing  react ion together with [125I]IL- 
1~. In parallel,  [~25I]IL-l~ b ind ing  was competed by 
IL- l f l .  As can clearly be seen from Fig. 2, I L - l ra  in the 
range of  1-15 t imes the IL-lc~ concent ra t ion  efficiently 
and  selectively antagonized the b ind ing  and cross- l ink- 
ing of  IL-lc~ to the 80 kDa IL-1 receptor, whereas b ind-  
ing and  cross- l ink ing to the 60 kDa receptor  remained 
practical ly unaffected. In contrast ,  IL - l f l  prevented 
b ind ing  of  I L - I~  to both  receptor types present on 
3. RESULTS AND DISCUSSION 
3.1. Two types o f  lL-1 receptors are present on D ION 
cells 
Cross- l ink ing of  [~25I]IL-l~ to EI  4 6.1 cells and  
D 1 ON cells resulted in the previously observed autora-  
d iographic  pictures [9]: a band at about  97-120 kDa in 
EI  4 6.1 (Fig. la)  cor respond ing  to the type I IL-1 
receptor  and,  in D10N cells a band at about  97-120 
kDa plus a band of  lower molecu lar  weight (Fig. lb).  
This second band was obvious ly  stronger when cells 
were cu l tured in the presence of  ConA,  which was also 
observed previously by Solari [9] in D10 G4.1 cells, and  
expla ined as induct ion  of  this type of  receptor  by ConA.  
Compar i son  with the PCR exper iments  (Fig. 3), how- 
ever, indicates that  the enhancement  of the lower molec- 
ular  weight band might  equal ly  well be at t r ibuted to an 
effect o f  ConA on the cross- l ink ing itself than  to a real 
receptor induct ion.  
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Fig. 2. Inhibition of cross-linking of [~25I]IL-lc~ to DION cells by the 
IL-1 receptor antagonist (RA) and IL-lfl. In the control (ctrl) 20 ng 
[~25I]IL-1~ was used. IL-lra and IL-lfl were present during binding 
and cross-linking with the concentrations i dicated. 
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Fig. 3. (a) Amino acid sequences of the extracellular domain of IL-1 receptors type I (2) and II (3). Identical amino acids are indicated by a vertical 
line, sequences the cDNA was taken from for PCR primers are highlighted. (b) Gel electrophoresis of PCR products. 1 pg RNA was reversely 
transcribed to cDNA and amplified with the different primer pairs with Taq polymerase in a final volume of 100/11. 20/11 were transferred to 1.5% 
agarose gel and electrophorized. Ethidiumbromide was present in the electrophoresis buffer. Lane 1, D10N cells cultured with ConA, primers for 
the type I IL-1 receptor; lane 2, D10N cells cultured with ConA, primers for the type II IL-1 receptor; lane 3, D10N cells cultured without ConA, 
primers for the type I IL-1 receptor; lane 4, D10N cells cultured without ConA, primers for the type II IL-I receptor; lane 5, El4 6.1 cells, primers 
for the type I IL-1 receptor; lane 6, El4 6.1 cells, primers for the type II IL-1 receptor; lane 7, control RNA applied from Perkin-Elmer with the 
PCR kit; lane 8, standard DNA, pBR 322 × HaeIII; numbers of base pairs: 587, 540, 504, 58, 434; 267, 234, 213, 192, 184; 124/123, 104, 89, 0, 
"64; lane 9, 70Z/3 cells, primers for the type I IL-1 receptor; lane 10, 70Z/3 cells, primers for the type II IL-1 receptor; lane 11, standard DNA 
as in lane 8. 
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D10N cells in a comparable manner. The results of 
these cross-linking experiments are in agreement with 
the characteristic of IL- lra to preferentially bind to the 
type I receptor of IL-1 [16]. 
3.3. The molecular nature of the IL-1 receptors on DION 
cells 
In order to clarify the molecular identity of the IL-1 
receptors of D10N cells, we isolated total RNA of 
D10N, EI4 and 70Zl3 cells, reversely transcribed the 
RNA to cDNA, and subjected the cDNA to a polym- 
erase chain reaction. The primers used in the PCR were 
specific for the type I and type II IL-1 receptor, respec- 
tively, and were chosen in a way to easily detect he PCR 
products by size on agarose gels. The sizes of the PCR 
products and the specificity of the primers used can be 
seen in Fig. 3a. The T cell EI4 6.1 only showed the PCR 
product of 363 base pairs corresponding to the type I 
receptor (Fig. 3b, lane 5) and no trace of type II receptor 
cDNA (Fig. 3b, lane 6). This is in line with the previous 
assumption, that T cells express exclusively type I IL-1 
receptors. In contrast, the pre B cell 70Z/3, showed a 
strong band at 414 base pairs with the primer pair for 
the type II IL-1 receptor cDNA (Fig. 3b, lane 10), but 
also two faint bands in the PCR reaction with the type 
I IL-1 receptor primer pair (Fig. 3b, lane 9), from which 
one corresponds to the expected type I PCR product. 
This supports the assumption that a minor amount of 
the type I IL-1 receptors may be expressed on 70Z/3 
cells [17] and B cells in general [11]. The data can further 
explain that IL- lra binds to 70Z/3 cells [18] although it 
has been shown that IL- lra had a very low affinity to 
the type II IL-1 receptor [16]. In the Th2 D10N cells 
finally, PCR yielded products with primers for both, the 
type I and type II IL-1 receptor, with comparable inten- 
sity and independent of the presence of ConA in the 
culture medium (see Fig. 3b, lane 14).  Thus, both types 
of receptors are expressed in this T helper cell line in 
roughly equivalent amounts, at least at the RNA level. 
In combination with the cross-linking experiments, 
there is little doubt that both types of IL-1 receptors are 
present in D10N cells also at the protein level. The data 
further show that the two prominent IL-1 binding pro- 
teins detectable in cross-linking experiments represent 
the type I and the type II IL-1 receptors, previously 
thought o characterize T and B cells, respectively. 
3.4. IL-lra inhibits IL-l-dependent proliferation of 
DION cells 
As a presumed physiological function of the type I 
IL-1 receptor the proliferative response of D10N cells 
to IL-I~ was measured and further specified by demon- 
stration of inhibition by IL-lra. As is seen from Fig. 4 
D10N cells, if previously starved for IL-1, dose-depen- 
dently proliferate upon IL-1 addition showing a half- 
maximum response at about 3 pg IL-1/ml. In the pres- 
ence of 33 ng IL-lra/ml the dose-response curve is 
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Fig. 4. Inhibition of the IL-l~-dependent proliferation of DION cells 
by the 1L-1 receptor antagonist. Cells were cultured without C ~) and 
with (e) 33 ng IL-lra/ml and the indicated concentration f IL-I~. 
Further details ee section 2, 
shifted to roughly 10-fold higher concentrations. This 
observation reveals that the proliferation of D10N cells 
by IL-1 is mediated by a IL-lra-sensitive receptor, i.e. 
the type I receptor. 
Although the Th2 cell line D10N used in this investi- 
gation is not entirely identical to those in which Savage 
et al. (D10S) [8] and Solari et al. (D10.G.4.1) [9,10] 
observed a low molecular weight IL-1 receptor, it is 
tempting to speculate from our molecular characteriza- 
tion of the 60 kDa receptor as type II IL-1 receptor that 
coexpression is a general characteristic of Th2 cells. 
Interestingly, this phenomenon is not shared by Thl 
cells which according to Solari et al. [10] only express 
the type II IL-1 receptor, do not express any IL-1 recep- 
tor according to Lichtman [19], and do not proliferate 
upon IL-1 exposure [20]. The expression pattern of IL-1 
receptors might therefore be a further criterion to differ- 
entiate Thl from Th2 cells. 
The differential expression of IL-1 receptors in T 
helper cell subsets will certainly also contribute to a 
better understanding of their function. Although the 
mode of signaling upon IL-1 binding to any of its recep- 
tors and the physiological consequences thereof may be 
only at the beginning of understanding [21], it appears 
conceivable that the proliferative IL-1 response of 
D10N cells is mediated by the type I receptor. This view 
is also supported by the finding that the proliferative 
response of D10N cells is inhibited by IL- lra which 
hardly, if at all effects binding of IL-1 to the type II 
receptor (Fig, 2 and [15]). The physiological role of the 
type II receptor in Th2 cells, however, remains to be 
established. 
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